Zydus signs agreement with TLC to commercialise black fungus treatment drug

Zydus Cadila, a leading pharmaceutical company, announced today that it has entered into a licence supply & commercialisation agreement with Taiwan Liposome Company (TLC), a Taiwan-based pharmaceutical company.   

Liposomal Amphotericin B is a critical drug, which is used to treat Mucormycosis or black fungus infection. As per the agreement, TLC will manufacture and supply AmphoTLC (Liposomal Amphotericin B) on a non-exclusive basis to Zydus, which will, in turn, commercialise & distribute the drug in India.    

AmphoTLC of 50 mg strength is a new drug application (NDA) of TLC, which has been approved by Central Drugs Standard Control Organisation (CDSCO) of India for immediate importation according to the approved usage & indication. It is the first and only complex generic drug found to be equivalent to Gilead’s AmBisome, which is the safest version of Amphotericin B in the world. Keeping in mind, the surge of black fungus infections in the recent days, the importation & distribution of the drug thereafter will address the acute shortage of Liposomal Amphotericin B in India.   

At the time of market close on Wednesday, the share price of Cadila Healthcare Ltd was trading at Rs 627.90, a rise of 0.88 per cent over its previous day’s closing price of Rs 622.45 on BSE.